يعرض 1 - 10 نتائج من 17 نتيجة بحث عن '"Wuerstlein, R"', وقت الاستعلام: 1.21s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

    المؤلفون: Harbeck, N.1,2 (AUTHOR) nadia.harbeck@med.uni-muenchen.de, Fasching, P.A.3 (AUTHOR), Wuerstlein, R.1,2 (AUTHOR), Degenhardt, T.1,4 (AUTHOR), Lüftner, D.5,6 (AUTHOR), Kates, R.E.2 (AUTHOR), Schumacher, J.7 (AUTHOR), Räth, P.7 (AUTHOR), Hoffmann, O.8 (AUTHOR), Lorenz, R.9 (AUTHOR), Decker, T.10 (AUTHOR), Reinisch, M.11,12 (AUTHOR), Göhler, T.13 (AUTHOR), Staib, P.14 (AUTHOR), Gluz, O.2 (AUTHOR), Schinköthe, T.15,16 (AUTHOR), Schmidt, M.17 (AUTHOR)

    المصدر: Annals of Oncology. Aug2023, Vol. 34 Issue 8, p660-669. 10p.

    مصطلحات موضوعية: *HORMONE receptor positive breast cancer, *METASTATIC breast cancer, *HORMONE therapy, *EPIDERMAL growth factor receptors, *PATIENT participation, *CANCER patients

    الشركة/الكيان: EUROPEAN Union


    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.

    المؤلفون: Gennari, A.1,2 (AUTHOR) alessandra.gennari@uniupo.it, Brain, E.3 (AUTHOR), De Censi, A.4 (AUTHOR), Nanni, O.5 (AUTHOR), Wuerstlein, R.6 (AUTHOR), Frassoldati, A.7 (AUTHOR), Cortes, J.8,9 (AUTHOR), Rossi, V.2 (AUTHOR), Palleschi, M.10 (AUTHOR), Alberini, J.L.11 (AUTHOR), Matteucci, F.12 (AUTHOR), Piccardo, A.13 (AUTHOR), Sacchetti, G.14 (AUTHOR), Ilhan, H.15 (AUTHOR), D'Avanzo, F.2 (AUTHOR), Ruffilli, B.1 (AUTHOR), Nardin, S.16 (AUTHOR), Monti, M.5 (AUTHOR), Puntoni, M.17 (AUTHOR), Fontana, V.18 (AUTHOR)

    المصدر: Annals of Oncology. Jun2024, Vol. 35 Issue 6, p549-558. 10p.

    مصطلحات موضوعية: *METASTATIC breast cancer, *EPIDERMAL growth factor receptors, *POSITRON emission tomography, *AORTIC valve insufficiency


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    206P Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients.

    المؤلفون: Wuerstlein, R1 (AUTHOR), Harbeck, N1 (AUTHOR), Grischke, E-M2 (AUTHOR), Forstmeyer, D3 (AUTHOR), Schumann, R von4 (AUTHOR), Krabisch, P5 (AUTHOR), Nitz, U4 (AUTHOR), Gluz, O4 (AUTHOR), Kates, R E6 (AUTHOR), Graeser, M4 (AUTHOR)

    المصدر: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

    مصطلحات موضوعية: *BREAST cancer patients, *CANCER chemotherapy, *MEDICAL sciences, *WOMEN'S hospitals, *CANCER

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial.

    المؤلفون: Gluz, O.1,2,3 (AUTHOR) oleg.gluz@wsg-online.com, Kuemmel, S.1,4,5 (AUTHOR), Nitz, U.1,2 (AUTHOR), Braun, M.6 (AUTHOR), Lüdtke-Heckenkamp, K.7 (AUTHOR), von Schumann, R.2 (AUTHOR), Darsow, M.8,9 (AUTHOR), Forstbauer, H.10 (AUTHOR), Potenberg, J.11 (AUTHOR), Uleer, C.12 (AUTHOR), Grischke, E.M.13 (AUTHOR), Aktas, B.14,15 (AUTHOR), Schumacher, C.16 (AUTHOR), zu Eulenburg, C.1,17 (AUTHOR), Kates, R.1 (AUTHOR), Jóźwiak, K.18 (AUTHOR), Graeser, M.1,2,19 (AUTHOR), Wuerstlein, R.1,20 (AUTHOR), Baehner, R.21 (AUTHOR), Christgen, M.22 (AUTHOR)

    المصدر: Annals of Oncology. Jun2023, Vol. 34 Issue 6, p531-542. 12p.

    مصطلحات موضوعية: *HORMONE receptor positive breast cancer, *EPIDERMAL growth factor receptors, *CLINICAL trials, *BREAST cancer, *PACLITAXEL, *EPIRUBICIN

    النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆.

    المؤلفون: Montemurro, F.1 filippo.montemurro@ircc.it, Delaloge, S.2, Barrios, C.H.3, Wuerstlein, R.4, Anton, A.5, Brain, E.6, Hatschek, T.7, Kelly, C.M.8, Peña-Murillo, C.9, Yilmaz, M.10, Donica, M.11, Ellis, P.12,13

    المصدر: Annals of Oncology. Oct2020, Vol. 31 Issue 10, p1350-1358. 9p.

    مصطلحات موضوعية: *BRAIN metastasis, *EPIDERMAL growth factor receptors, *HER2 protein, *BREAST cancer, *TRASTUZUMAB, *CANCER patients

    النص الكامل

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR— phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

    المؤلفون: Nitz, U. A.1,2, Gluz, O.1,2,3 oleg.gluz@wsg-online.com, Christgen, M.4, Grischke, E.-M.5, Augustin, D.6, Kuemmel, S.7, Braun, M.8, Potenberg, J.9, Kohls, A.10, Krauss, K.11, Stefek, A.12, Schumacher, C.13, Forstbauer, H.14, Reimer, T.15, Fischer, H.16, Liedtke, C.17,18, Wuerstlein, R.19, Schumacher, J.20, Kates, R.1, Kreipe, H.3

    المصدر: Annals of Oncology. Nov2017, Vol. 28 Issue 11, p2768-2772. 5p. 1 Graph.

    مصطلحات موضوعية: *BREAST cancer, *TRASTUZUMAB, *PACLITAXEL, *CANCER chemotherapy, *TUMORS, *CANCER cells

    النص الكامل

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    Central venous access in oncology: ESMO Clinical Practice Guidelines.

    المؤلفون: Sousa, B.1, Furlanetto, J.2, Hutka, M.3, Gouveia, P.1, Wuerstlein, R.4, Mariz, J. M.5, Pinto, D.1, Cardoso, F.1

    المصدر: Annals of Oncology. 2015 Suppl. 5, Vol. 26, pv152-v168. 17p. 1 Diagram, 6 Charts.

    مصطلحات موضوعية: *CENTRAL venous catheters, *CANCER treatment, *ONCOLOGY, *GUIDELINES, *CANCER patients, *VENOUS puncture

    النص الكامل

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772]

    المؤلفون: Nitz, U.A.1,2 (AUTHOR), Gluz, O.1,2,3 (AUTHOR) oleg.gluz@wsg-online.com, Christgen, M.4 (AUTHOR), Grischke, E.-M.5 (AUTHOR), Augustin, D.6 (AUTHOR), Kuemmel, S.7 (AUTHOR), Braun, M.8 (AUTHOR), Potenberg, J.9 (AUTHOR), Kohls, A.10 (AUTHOR), Krauss, K.11 (AUTHOR), Stefek, A.12 (AUTHOR), Schumacher, C.13 (AUTHOR), Forstbauer, H.14 (AUTHOR), Reimer, T.15 (AUTHOR), Fischer, H.16 (AUTHOR), Liedtke, C.17,18 (AUTHOR), Wuerstlein, R.19 (AUTHOR), Schumacher, J.20 (AUTHOR), Kates, R.1 (AUTHOR), Kreipe, H.3 (AUTHOR)

    المصدر: Annals of Oncology. Mar2022, Vol. 33 Issue 3, p355-355. 1p.

    مصطلحات موضوعية: *HER2 positive breast cancer, *TRASTUZUMAB

    النص الكامل

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial.

    المؤلفون: Graeser, M.1, Gluz, O.2, Biehl, C.3, Ulbrich-Gebauer, D.4, Palatty, J.3, Christgen, M.5, Kuemmel, S.6, Grischke, E-M.7, Augustin, D.8, Braun, M.9, Potenberg, J.10, Wuerstlein, R.11, Eulenburg, C.1, Kates, R.1, Kolberg-Liedtke, C.12, Feuerhake, F.5, Kreipe, H.5, Nitz, U.2, Harbeck, N.13

    المصدر: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS48-S48. 1p.

    مصطلحات موضوعية: *NEOADJUVANT chemotherapy, *BREAST cancer treatment, *TREATMENT effectiveness

    النص الكامل

    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    55P Molecular risk factors for distant metastases in premenopausal patients with HR+/HER2- EBC.

    المؤلفون: Ni, H.1, Kumbrink, J.2, Mayr, D.2, Seiler, A.1, Hagemann, F.1, Degenhardt, T.1, Sagebiel, S.2, Wuerstlein, R.1, Harbeck, N.1, Eggersmann, T.K.1

    المصدر: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS44-S44. 1p.

    مصطلحات موضوعية: *METASTATIC breast cancer, *PERIMENOPAUSE, *MOLECULAR oncology

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث